Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: Need for team care
Challenges in the treatment of patients coinfected with HIV and hepatitis C virus: Need for team care
复制标题
DOI：
10.1086/427452
复制
发表时间：
2005-04-15
影响因子：
11.8
通讯作者：
Nunes, D
中科院分区：
文献类型：
--
作者：
Fleming, CA;Tumilty, S;Nunes, D
我们估计，只有三分之一的丙型肝炎病毒（HCV）和人类免疫缺陷病毒（HIV）合并感染的患者有资格接受干扰素（IFN）和利巴韦林治疗HCV，而在那些有资格的患者中，三分之二的人拒绝治疗。到目前为止，我们已经开始用干扰素和利巴韦林治疗8%的合并感染患者，< 1%的患者有持续的病毒学应答。在此过程中，我们发现了许多问题，这些问题严重限制了我们在该人群中开始和完成IFN治疗的能力，并将这些困难分为4个主要挑战。它们包括获得护理，禁忌症或治疗障碍，患者不愿意开始IFN治疗，以及治疗耐受性低。如果合并感染HCV和HIV的患者要接受更多的丙型肝炎治疗，这些问题将需要解决。
We estimate that only one-third of patients coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are eligible for therapy for HCV with interferon (IFN) and ribavirin, and, of those who are eligible, two-thirds decline treatment. To date we have initiated treatment with IFN and ribavirin for 8% of coinfected patients evaluated, and < 1% of patients have had a sustained virological response. During this process, we have identified many problems that significantly limit our ability to initiate and complete treatment with IFN in this population and have categorized these difficulties into 4 main challenges. They include access to care, contraindications or barriers to treatment, patients' reluctance to start treatment with IFN, and the low tolerability of treatment. If patients coinfected with HCV and HIV are to be treated for hepatitis C in greater numbers, these issues will need to be addressed.